[{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Rabies Immune Globulin (Human)","moa":"Rabies Virus Proteins","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center"},{"orgOrder":0,"company":"Kamada","sponsor":"Fernanda P Silveira","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cytomegalovirus Immunoglobulin","moa":"CMV","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Fernanda P Silveira","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ Fernanda P Silveira"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Cytomegalovirus Immune Globulin is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Cytomegalovirus Infections.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 06, 2025

                          Lead Product(s) : Cytomegalovirus Immunoglobulin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Fernanda P Silveira

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 28, 2023

                          Lead Product(s) : Cefiderocol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Lead Product(s) : Piperacillin Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 02, 2022

                          Lead Product(s) : Piperacillin Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : The study of KEDRAB® (Rabies Immune Globulin [Human]) conducted in children was the first and only pediatric study for any HRIG available in U.S. The study met its primary objective, which was to confirm the safety of KEDRAB in the pediatric population.

                          Product Name : Kedrab

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 19, 2020

                          Lead Product(s) : Rabies Immune Globulin (Human)

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Kedrion

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 27, 2018

                          Lead Product(s) : Oseltamivir Phosphate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Lead Product(s) : Piperacillin Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase IV

                          Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 14, 2018

                          Lead Product(s) : Piperacillin Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank